A Phase 1/2 Study Evaluating the Safety andEfficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells(BEAM-101) to Increase Fetal Hemoglobin (HbF) Production in Patients with Severe SickleCell Disease

Project: Research project

Project Details

Description

A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) to Increase Fetal Hemoglobin (HbF) Production in Patients with Severe Sickle Cell Disease
StatusActive
Effective start/end date9/1/229/30/27

Funding

  • BEAM THERAPEUTICS INC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.